FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERα/cyclin D1/Rb axis

BACKGROUND: Tamoxifen is an important choice in endocrine therapy for patients with oestrogen receptor-positive (ER+) breast cancer, and disease progression-associated resistance to tamoxifen therapy is still challenging. Flap endonuclease-1 (FEN1) is used as a prognostic biomarker and is considered...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lu, Shen, Ji-Ming, Qu, Jing-Lei, Song, Na, Che, Xiao-Fang, Hou, Ke-Zuo, Shi, Jing, Zhao, Lei, Shi, Sha, Liu, Yun-Peng, Qu, Xiu-Juan, Teng, Yue-E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940940/
https://www.ncbi.nlm.nih.gov/pubmed/33708885
http://dx.doi.org/10.21037/atm-20-3068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940940/
https://www.ncbi.nlm.nih.gov/pubmed/33708885
http://dx.doi.org/10.21037/atm-20-3068

Ejemplares similares